Switzerland
Roche, founded in 1896, is a prominent player in the Pharmaceutical industry, headquartered in Switzerland. As a global leader in both pharmaceuticals and diagnostics, Roche combines these strengths to pioneer advancements in personalised healthcare. The company excels in providing targeted treatments across various sectors, including oncology, immunology, and infectious diseases.
With a status as the world’s largest biotech company, Roche offers truly differentiated medicines. Its leadership in in vitro diagnostics and tissue-based cancer diagnostics, alongside diabetes management, underscores its comprehensive healthcare prowess. Significantly, thirty of Roche’s medicines are recognized on the World Health Organization Model Lists of Essential Medicines, highlighting their global impact.
Recently, on March 1, 2026, Roche secured a $7.50B Post IPO Debt investment from Deutsche Bank, emphasizing its financial stability and growth potential. Consistently demonstrating sustainability, Roche has maintained its position as the Group Leader in sustainability for a decade within the Pharmaceuticals, Biotechnology & Life Sciences Industry according to the Dow Jones Sustainability Indices.
